In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block ...

Participation of endothelin in salt-sensitive essential hypertension could be mediated by a deficit in its natriuretic actions, or by an exaggerated contribution to the control of vasoconstriction ...

There is increasing evidence that endothelin-1 has a pathogenic role in pulmonary arterial hypertension 10 and that blockade of endothelin receptors may be beneficial. 11 Endothelin-1 is a potent ...

The dual endothelin-receptor antagonist macitentan was developed by modifying the structure of bosentan to increase efficacy and safety. 14 Macitentan is characterized by sustained receptor ...

Akihiro Inoue, Masashi Yanagisawa, Sadao Kimura, Yoshitoshi Kasuya, Takashi Miyauchi, Katsutoshi Goto, Tomoh Masaki, The Human Endothelin Family: Three Structurally and Pharmacologically Distinct ...

Key TakeawaysErythritol damages brain blood vessel cells, increasing risk of blood clots and stroke in lab studies. It ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

TRYVIO (aprocitentan) is an endothelin receptor antagonist that inhibits the binding of endothelin (ET)-1 to ET A and ET B receptors. 1,2 The effects of ET-1 bear many similarities with the ...

Tezosentan a dual endothelin A/endothelin B receptor (ETA/ETB) blocker caused a dose-dependent increase in cardiac index ranging from 24.4% to 49.9%, versus 3% with placebo.

CHICAGO, IL—Use of an investigational endothelin receptor antagonist in patients with resistant hypertension has a significant impact on both automated office and 24-ambulatory blood pressure when ...